A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Neoplasm Metastasis
Interventions: DRUG: Imlunestrant|DRUG: Exemestane|DRUG: Fulvestrant|DRUG: Abemaciclib
Sponsor: Eli Lilly and Company